# Editorial: Future directions and current trends in cellular therapies

**Authors:** Ruxandra Irimia, Eleni Gavriilaki

PMC · DOI: 10.3389/fmed.2025.1732925 · 2025-11-12

## Full-text entities

- **Genes:** HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}
- **Diseases:** AML (MESH:D015470), viral enteritis (MESH:D053489), hematologic malignancies (MESH:D019337), marrow failure (MESH:D000080983), CMV (MESH:D003586), CMV viremia (MESH:D014766), myeloma (MESH:D009101), SN (MESH:D009369), EBV (MESH:D020031), mantle cell lymphoma (MESH:D020522), diffuse large B-cell lymphoma (MESH:D016403), -cell (MESH:D002292), infectious (MESH:D003141), B-cell malignancies (MESH:D016393), infection (MESH:D007239), ALL (MESH:D054198), follicular lymphoma (MESH:D008224)
- **Chemicals:** venetoclax (MESH:C579720), letermovir (MESH:C000588473)
- **Species:** Human betaherpesvirus 6 (species) [taxon 10368], Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12646882